A ranar 12 ga Mayu, 2025, CARsgen ta sanar da bayanan asibiti na farko don CT0596, wani nau'in CAR-T mai niyya ga BCMA wanda aka haɓaka ta amfani da dandamalin THANK-u Plus™. A halin yanzu ana tantance CT0596 a cikin wani bincike na asibiti na farko don sake dawowa/ragewa (R/R MM) ko kuma sake dawowa/ragewa daga cutar sankarar jini ta ƙwayoyin plasma (R/R PCL) don tantance amincinsa, da kuma ingancinsa na farko.
Ya zuwa ranar 6 ga Mayu, 2025, an yi wa marasa lafiya 8 da ke fama da R/R MM waɗanda suka sami aƙalla layuka uku na magani a baya rajista kuma an saka musu CT0596 bayan an cire lymphostasis ɗinsu tare da tsarin FC (fludarabine 22.5-30 mg/m² da cyclophosphamide 350-500 mg/m²). Manyan abubuwan da aka gano daga har zuwa watanni huɗu na bin diddigin sun haɗa da:
Ba a bayar da rahoton wani abu mai guba da ke iyakance yawan shan magani ba (DLTs), ≥Grade 3 cytokine release syndrome (CRS), immune effector cell effector neurotoxicity syndrome (ICANS), ko graft-versus-host disease (GVHD). Samfurin ya nuna kyakkyawan yanayin aminci, ba tare da wani mara lafiya da ya daina magani saboda abubuwan da suka faru marasa kyau ba.
1) Daga cikin marasa lafiya 5 da suka kammala tantancewar farko ta inganci a Mako na 4, marasa lafiya 3 (60%) sun sami cikakken amsa/cikakken amsa (sCR/CR), kuma marasa lafiya 4 (80%) sun sami ƙarancin sauran cututtukan da suka rage (MRD) - rashin daidaito a cikin ƙashin ƙashi. 2) Bayanan farko na inganci daga marasa lafiya 2 a Rana ta 14 sun nuna raguwar raunukan da za a iya aunawa da ≥92% da ≥65%, bi da bi. 3) Marasa lafiya 1 bai kai ga lokacin kimantawa ta inganci da aka ƙayyade ta hanyar yarjejeniya ba tukuna.
Duk marasa lafiya da suka kamu da cutar sCR/CR sun ci gaba da samun kulawa, ciki har da majiyyaci na farko da ya kammala binciken watanni huɗu.
Dangane da bayanan farko na aminci da inganci, CT0596 ya nuna kyakkyawan juriya da kuma ƙarfafa alamun inganci ga marasa lafiya da ke fama da cutar R/R MM a duk matakan da aka riga aka ayyana, tare da lura da faɗaɗa CAR-T. Waɗannan binciken sun ba da damar ƙarin bincike ba kawai a cikin R/R MM ba, har ma a cikin wasu cututtukan ƙwayoyin plasma da cututtukan da ke haifar da garkuwar jiki waɗanda ƙwayoyin plasma masu amsawa ke shiga tsakani.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Lokacin Saƙo: Mayu-15-2025